Global Cancer Biosimilars Market Outlook By Biologic class
Global Cancer Biosimilars Market Outlook By Type
Global Cancer Biosimilars Market Outlook By Drug Class
Global Cancer Biosimilars Market Outlook By Route Of Administration
Global Cancer Biosimilars Market Outlook By Distribution channel
Global Cancer Biosimilar Market Outlook By Region
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Cancer Biosimilars Market Snapshot
Chapter 4. Global Cancer Biosimilars Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Biologic Class Estimates & Trend Analysis
5.1. By Biologic Class & Market Share, 2021 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2024 to 2034 for the following By Biologic Class:
5.2.1. Bevacizumab
5.2.2. Rituximab
5.2.3. Trastuzumab
5.2.4. Filgrastim
5.2.5. Pegfilgrastim
5.2.6. Denosumab
5.2.7. Others (Products approved in developing countries & pipeline products)
Chapter 6. Market Segmentation 2: By Type Estimates & Trend Analysis
6.1. By Type & Market Share, 2021 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2024 to 2034 for the following By Type:
6.2.1. Lung Cancer
6.2.2. Breast cancer
6.2.3. Ovarian cancer
6.2.4. Prostate cancer
6.2.5. Lymphoma
6.2.6. Others
Chapter 7. Market Segmentation 3: By Drug Class Estimates & Trend Analysis
7.1. By Drug Class & Market Share, 2021 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2024 to 2034 for the following By Drug Class:
7.2.1. G-CSF
7.2.2. Monoclonal Antibody
Chapter 8. Market Segmentation 4: By Route of Administration Estimates & Trend Analysis
8.1. By Route of Administration & Market Share, 2021 & 2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2024 to 2034 for the following By Route of Administration:
8.2.1. Intravenous
8.2.2. Subcutaneous
8.2.3. Others
Chapter 9. Market Segmentation 5: By Distribution Channel Estimates & Trend Analysis
9.1. By Distribution Channel & Market Share, 2021 & 2034
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2024 to 2034 for the following By Distribution Channel:
9.2.1. Hospital Pharmacy
9.2.2. Retail Pharmacy
9.2.3. Online Pharmacy
9.2.4. Others
Chapter 10. Cancer Biosimilars Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. North America
10.1.1. North America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Biologic Type, 2025 - 2034
10.1.2. North America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Type, 2025 - 2034
10.1.3. North America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Drug Class, 2025 - 2034
10.1.4. North America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2025 - 2034
10.1.5. North America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2025 - 2034
10.1.6. North America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts by country, 2025 - 2034
10.2. Europe
10.2.1. Europe Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Biologic Type, 2025 - 2034
10.2.2. Europe Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Type, 2025 - 2034
10.2.3. Europe Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Drug Class, 2025 - 2034
10.2.4. Europe Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2025 - 2034
10.2.5. Europe Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2025 - 2034
10.2.6. Europe Cancer Biosimilars Market revenue (US$ Million) by country, 2025 - 2034
10.3. Asia Pacific
10.3.1. Asia Pacific Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Biologic Type, 2025 - 2034
10.3.2. Asia Pacific Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Type, 2025 - 2034
10.3.3. Asia Pacific Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Drug Class, 2025 - 2034
10.3.4. Asia Pacific Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2025 - 2034
10.3.5. Asia Pacific Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2025 - 2034
10.3.6. Asia Pacific Cancer Biosimilars Market revenue (US$ Million) by country, 2025 - 2034
10.4. Latin America
10.4.1. North America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Biologic Type, 2025 - 2034
10.4.2. Latin America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Type, 2025 - 2034
10.4.3. Latin America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Drug Class, 2025 - 2034
10.4.4. Latin America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2025 - 2034
10.4.5. Latin America Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2025 - 2034
10.4.6. Latin America Cancer Biosimilars Market revenue (US$ Million) by country, (US$ Million) 2025 - 2034
10.5. Middle East & Africa
10.5.1. Middle East & Africa Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Biologic Type, 2025 - 2034
10.5.2. Middle East & Africa Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Type, 2025 - 2034
10.5.3. Middle East & Africa Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Drug Class, 2025 - 2034
10.5.4. Middle East & Africa Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2025 - 2034
10.5.5. Middle East & Africa Cancer Biosimilars Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2025 - 2034
10.5.6. Middle East & Africa Cancer Biosimilars Market revenue (US$ Million) by country, (US$ Million) 2025 - 2034
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Mylan
11.2.2. Amgen
11.2.3. Pfizer
11.2.4. Celltrion
11.2.5. Samsung Bioepis
11.2.6. Bio-Thera Solutions
11.2.7. Sandoz (Novartis)
11.2.8. Teva
11.2.9. Coherus BioSciences
11.2.10. CuraTeQ Biologics
11.2.11. Accord Healthcare
11.2.12. Allergan
11.2.13. Biocon
11.2.14. Merck
11.2.15. Accord BioPharma
11.2.16. Accord Healthcare S.L.U.
11.2.17. AffaMed
11.2.18. Biosimilar Collaborations Ireland Limited
11.2.19. Dr. Reddy’s
11.2.20. Henlius
11.2.21. Intas
11.2.22. Mabxience
11.2.23. Nippon Kayaku
11.2.24. Sandoz GmbH
11.2.25. Amgen Inc.
11.2.26. Amneal Pharmaceuticals, Inc.
11.2.27. Betta Pharmaceuticals/Beijing Mabworks
11.2.28. Bio-Thera Solutions, Ltd.
11.2.29. Celltrion, Inc.
11.2.30. Cipla
11.2.31. Dr. Reddy’s Laboratories
11.2.32. FGK Representative Service GmbH
11.2.33. Hetero
11.2.34. Innovent Biologics
11.2.35. mAbxience Holding, S.L.
11.2.36. Outlook Therapeutics Limited
11.2.37. Pfizer Inc.
11.2.38. Roche Registration GmbH
11.2.39. Samsung Bioepis NL B.V.
11.2.40. Sandoz Inc.
11.2.41. Shanghai Henlius Biotech
11.2.42. STADA Arzneimittel AG
11.2.43. TOT BIOPHARM
11.2.44. AstraZeneca PLC
11.2.45. Samsung Bioepis Co., Ltd.
11.2.46. Organon & Co.
11.2.47. Other Prominent Player
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.